Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5.6% – Here’s What Happened

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price rose 5.6% on Monday . The stock traded as high as $13.80 and last traded at $13.80. Approximately 460,344 shares were traded during trading, a decline of 62% from the average daily volume of 1,196,887 shares. The stock had previously closed at $13.07.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CAPR. HC Wainwright restated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Cantor Fitzgerald boosted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler began coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Maxim Group lifted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Up 5.4 %

The firm has a 50 day moving average price of $17.94 and a two-hundred day moving average price of $10.33. The firm has a market capitalization of $626.12 million, a price-to-earnings ratio of -12.99 and a beta of 3.98.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CAPR. SG Americas Securities LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth $133,000. The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics in the 3rd quarter worth $161,000. Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the 3rd quarter valued at about $192,000. BNP Paribas Financial Markets grew its stake in shares of Capricor Therapeutics by 868.7% during the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 15,872 shares in the last quarter. Finally, FMR LLC acquired a new stake in shares of Capricor Therapeutics during the third quarter valued at about $370,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.